Sage Journals: Discover world-class research

Abstract

Oxidative coupling of 2-methylquinolines with quinoxalines via a TBHP (t-butyl hydroperoxide) and TFA (trifluoroacetic acid) mediated Minisci reaction affords quinolin-2-yl(quinoxalin-2-yl)methanone derivatives. This approach provides a simple and efficient method to construct various acyl derivatives in moderate to good yields (45%–92%) without any metal catalyst. Mechanistically, homolytic aromatic substitution (HAS) of acyl radicals mediated by TBHP is crucial for the construction of the quinolin-2-yl(quinoxalin-2-yl)methanone products.

Keywords

2-methylquinolines homolytic aromatic substitution quinolin-2-yl(quinoxalin-2-yl)methanones quinoxalines TFA/TBHP

Introduction

Acyl N-heterocycles, for example, the quinolin-2-yl(quinoxalin-2-yl)methanones reported in this article, play key roles in pharmaceuticals^1–3 and possess different biological activities such as antimicrobial,⁴ antipsychotic,⁵ antithrombotic,⁶ antitussive,⁷ and antihpyerglycemic.⁸ There have been numerous reports on the preparation of electron-deficient heterocycles, but examples on their functionalization by oxidative coupling are rare. Compared to electron-rich heterocycles,^9–13 the acylation of electron-deficient heterocycles is more difficult. It is worth mentioning that the Minisci reaction and aromatic homolytic substitution can overcome efficiently difficulties via nucleophilic acyl radical addition to protonated electron-deficient heterocycles.^14,15 Recently, several researchers reported the preparation of acyl N-heterocycles using the Minisci reaction. Yuan et al.¹⁶ reported that 3-acylated quinoxalin-2(1H)-ones could be obtained by oxidative coupling of quinoxalin-2(1H)-ones with diverse aldehydes. Meanwhile, Siddaraju et al.¹⁷ reported that acylations of isoquinoline, quinoline, and quinoxaline derivatives could be accomplished by employing cross dehydrogenative coupling reactions with aldehydes using a substoichiometric amount of TBAB (tetrabutylammonium bromide) and K₂S₂O₈ as the oxidant. Zhang et al.¹⁸ showed that isoquinolin-1-yl(p-tolyl)methanones could be prepared by the reaction of isoquinoline with 4-methylbenzaldehyde catalyzed by TBHP under irradiation with blue LEDs. Furthermore, Rahim et al.¹⁹ reported that I₂/DMSO could promote the reactions of 2-methylquinolines with benzothiazoles to form 2-heteroaryl benzothiazoles under acid- and peroxide-free conditions. Also, Chen et al.²⁰ showed that TBHP/TFA could promote the reaction of isoquinolines with benzaldehydes to give the corresponding acyl derivatives. All these methods used aldehydes as acyl radical donors. However, Ali et al.²¹ reported that acyl radicals derived from methylbenzenes could be utilized for the direct acylation of N-heterocycles promoted by AlCl₃ at 95 ^oC under N₂. Inspired by these examples, we envisaged that 2-methylquinolines could be used as acyl radical donors under oxidative conditions for the acylation of quinoxalines via intermolecular homolytic aromatic substitution of acyl radicals, and our studies proved this to be the case. Therefore, in this paper, we disclose the first oxidative coupling of 2-methylquinolines with quinoxalines via TBHP (t-butyl hydroperoxide) and TFA (trifluoroacetic acid) mediated Minisci reactions to prepare quinolin-2-yl(quinoxalin-2-yl)methanones without any metal catalyst. Homolytic aromatic substitution of acyl radicals mediated by TBHP is crucial in the mechanism of this process for the construction of acyl derivatives.

Results and discussion

Quinoxaline (1a) and 2-methylquinoline (2a) were selected as model substrates to optimize the reaction conditions for the synthesis of quinolin-2-yl(quinoxalin-2-yl) methanone (3a). The effects of different additives, oxidants, solvents and temperatures were investigated and the results are summarized in Table 1. First, different oxidants such as K₂S₂O₈, H₂O₂, O₂, and TBHP were screened and TBHP was found to be the best, affording a 60% yield of 3a (Table 1, entries 1–4). Next, different additives including AlCl₃, TFA, Ac₂O, and AcOH were investigated, with TFA to be the best (Table 1, entries 4–8). The yield of 3a was only 11% without any additive (Table 1, entry 5). Next, the solvent was optimized, and PhCl was found to be the most suitable leading to a 71% yield of 3a (Table 1, entries 6 and 9–12). With PhCl as the solvent, the reaction temperature was further optimized. When the temperature was increased from room temperature to reflux, the yield of 3a increased from 24% to 73% (Table 1, entries 4, 10 and 11), which indicated that the reaction proceeded best at 70 ^oC (Table 1, entries 12–15). To further improve the yield of 3a, the amount of TBHP was investigated (Table 1, entries 16–18), with 4.0 equivalents ensuring the best yield of 3a of 86%. So the optimum reaction conditions were established as follows: TBHP (4.0 equiv.) as the oxidant, TFA as the additive, and PhCl as the solvent at 70 ^oC for 12 h.

Table 1.

Optimization of the reaction conditions for the synthesis of 3a.^a.

Entry	Additive	Oxidant^b	Solvent	Temp (^oC)	Yield of 3a (%)^c
1	AlCl₃	K₂S₂O₈	DCE	70	trace
2	AlCl₃	H₂O₂	DCE	70	–
3	AlCl₃	O₂	DCE	70	trace
4	AlCl₃	TBHP	DCE	70	60
5	–	TBHP	DCE	reflux	11
6	TFA	TBHP	DCE	70	65
7	Ac₂O	TBHP	DCE	70	46
8	AcOH	TBHP	DCE	70	40
9	TFA	TBHP	DMSO	70	35
10	TFA	TBHP	CH3CN	70	32
11	TFA	TBHP	H2O	70	10
12	TFA	TBHP	PhCl	70	71
13	TFA	TBHP	PhCl	r.t.	24
14	TFA	TBHP	PhCl	100	72
15	TFA	TBHP	PhCl	reflux	73
16^d	TFA	TBHP	PhCl	70	76
17^e	TFA	TBHP	PhCl	70	86
18^f	TFA	TBHP	PhCl	70	85

Reaction conditions: 1a (1.0 mmol), 2a (3.0 mmol), additive (1.2 equiv), oxidant (2.0 equiv), solvent (8 mL), 12 h.

TBHP in decane (5–6 M).

Isolated yield.

TBHP (3.0 equiv).

TBHP (4.0 equiv).

TBHP (5.0 equiv).

With optimized conditions in hand, the substrate scope was next investigated. 2-Methylquinolines 2 possessing sp³ carbons and different substituents reacted with 1a via oxidative cross-dehydrogenative coupling to afford the corresponding products 3 in moderate to good yields ranging from 51% to 92% in Table 2. The electronic properties of the substituents were observed to affect the reaction yields to a degree. At the same carbons positions, 2-methylquinolines substituted with electron-donating groups (Table 2, entries 2, 4, 6, 9, and 11) gave slightly higher yields than the those with electron-withdrawing groups (Table 2, entries 3, 5, 7, 8, 10, and 12), the reason for this may be that the nucleophilicities of the acyl radicals derived from substrates with electron-donating groups surpassed those derived from substrates with electron-withdrawing groups. When electron-donating substitutents were attached at different positions of the quinoline ring, the order of the product yields was C-6 > C-8 > C-7 > C-4 > C-3 (Table 2, entries 2, 4, 6, 9, and 11). For electron-withdrawing substitutents, the order of the product yields was C-6 > C-7 > C-4 > C-3 > C-8 (Table 2, entries 3, 5, 7, 8, 10, and 12).

Table 2.

Substrate scope of various 2-methylquinolines 2 having sp³ carbons in the oxidative cross-dehydrogenative coupling reaction.^a

Entry	R	Product^b	Yield (%)^c
1	(2a) H	3a	86
2	(2b) 3-OCH₃	3b	59
3	(2c) 3-Br	3c	53
4	(2d) 4-OCH₃	3d	71
5	(2e) 4-Cl	3e	58
6	(2f) 6-OCH₃	3f	92
7	(2g) 6-Cl	3g	80
8	(2h) 6-Br	3h	83
9	(2i) 7-OCH₃	3i	73
10	(2j) 7-Cl	3j	62
11	(2k) 8-OCH₃	3k	79
12	(2l) 8-Br	3l	51

Reaction conditions: 1a (1.0 mmol), 2 (3.0 mmol), TFA (1.2 equiv), TBHP (4.0 equiv), PhCl (8 mL), 12 h.

Structures were confirmed by ¹H and ¹³C NMR spectroscopy.

Isolated yield based on 1a.

Subsequently, we set out to examine the substrate scope of quinoxalines 1 under the optimized conditions. The nature and the location of different R′ groups on quinoxalines 1 affected the reaction yields. At the same positions, quinoxalines substituted with electron-donating groups (Table 3, entries 1 and 3) gave slightly lower yields than those with electron-withdrawing groups (Table 3, entries 2 and 4). The reason for this may be due to the fact that the eletrophilicity of the protonated intermediate derived from the protonation of quinoxalines with electron-donating groups was weaker than those with electron-withdrawing groups. Due to the steric hindrance effect, when 2-methylquinoxaline and 2-chloroquinoxaline were employed (Table 3, entries 1 and 2), the yields of the products were lower than those of the corresponding 6-substituted quinoxalines (Table 3, entries 3 and 4). Besides, 6-methylquinoxaline reacted with 2a to generate an inseparable mixture of two regioisomeric acylated coupling products, and the yield ratio was 1:1, as determined by ¹H NMR (600 MHz, CDCl₃) analysis (Table 3, entry 3). The same was observed for 6-chloroquinoxaline (Table 3, entry 4).

Table 3.

Substrate scope of various quinoxalines 1.^a

Entry	R′	Product^b	Yield (%)^c
1	(1a) 2-CH₃	3m	45
2	(1b) 2-Cl	3n	49
3	(1c) 6-CH₃	3o	55(1:1)^d
3	(1c) 6-CH₃	3o′	55(1:1)^d
4	(1d) 6-Cl	3p	61(1:1)^d
4	(1d) 6-Cl	3p′	61(1:1)^d

Reaction conditions: 1 (1.0 mmol), 2a (3.0 mmol), TFA (1.2 equiv), TBHP (4.0 equiv), PhCl (8 mL), 12 h.

Structures were confirmed by ¹H and ¹³C NMR spectroscopy.

Isolated yield based on 1.

Ratio was determined by ¹H NMR (600 MHz, CDCl₃) analysis.

Finally, 2-methylpyridine (4) and quinoline (6) were investigated as substrates. 2-Methylpyridine 4 exhibited moderate reactivity with quinoxaline (1a) under the standard conditions and gave the corresponding product 5 in 41% yield. Quinoline (6) also exhibited moderate reactivity with 2-methylquinoline (2a) under the standard conditions and gave the corresponding product 7 in 39% yield (Scheme 1).

Scheme 1.

2-Methylpyridine (4) and quinoline (6) as substrates.

To further explore the mechanism of the oxidative coupling of 2-methylquinolines with quinoxalines, several control experiments were carried out. First, when adding the radical scavenger TEMPO (1.0 equiv) to the standard reaction, product 3a was only obtained in a trace amount (Scheme 2-a), which suggested that the reaction proceeded through a radical intermediate. Second, when 2a alone was subjected to the standard reaction conditions, a 95% yield of quinoline-2-carbaldehyde (8a) was observed (Scheme 2-b). Finally, when 1a was reacted with quinoline-2-carbaldehyde (8a) under the standard conditions, an 85% yield of 3a was obtained (Scheme 2-c), suggesting that quinoline-2-carbaldehyde was a crucial intermediate in this reaction.

Scheme 2.

Control experiments.

Based on these observations and related references,^22,23 a plausible mechanism for the cross-dehydrogenative coupling process is proposed in Scheme 3. TFA can coordinate with quinoxaline leading to the protonated intermediate (9a), which makes the quinoxaline ring more electron-deficient and increases the electrophilicity. TBHP undergoes homolytic cleavage to give a methyl radical along with a hydroxyl radical on heating. On the other hand, in the presence of excess TBHP, 2-methylquinoline (2a) is oxidized to quinolin-2-ylmethanol (10a) and is subsequently transforms into quinoline-2-carbaldehyde (8a). Next, 8a undergoes C–H bond homolysis and is transformed into acyl radical (11a) upon attack of the methyl radical or hydroxyl radical. This nucleophilic acyl radical (11a) can then attack smoothly at the high electrophilic C-1 site of the protonated intermediate (9a) and generates radical-cation intermediate (12a). A single-electron transfer (SET) from (12a) releases the N⁺ intermediate (13a). Simultaneously, the methyl radical or hydroxyl radical captures a single electron. Finally, oxidative coupling target product (3a) can be obtained by deprotonation of (13a).

Scheme 3.

A plausible mechanism for the formation of quinolin-2-yl(quinoxalin-2-yl)methanones.

Conclusion

In conclusion, we have developed a procedure for the oxidative coupling of 2-methylquinolines with quinoxaline via a TBHP/TFA-mediated Minisci reaction for the synthesis of quinolin-2-yl(quinoxalin-2-yl)methanones without any metal catalyst. This works shows that 2-methylquinolines can be used as acyl radical donors under oxidative conditions and be utilized for the acylation of quinoxalines via intermolecular homolytic aromatic substitution of acyl radicals. The reaction temperature is 70 ^oC, below the alarm temperature 75 ^oC and autoignition temperature 88 ^oC of TBHP, which shows that the reaction condition is relatively safe. This approach encompasses relatively mild reaction conditions and affords moderate to good yields.

Experimental

Melting points were measured on a Büchi B-540 capillary melting point apparatus and are uncorrected. Mass spectra (ESI-MS) were recorded on a Thermo Finnigan LCQ-Advantage spectrometer. High-resolution mass spectrometry (ESI-HRMS) was performed using an Agilent 6210 TOF instrument. ¹H NMR and ¹³C NMR spectra were recorded on a Bruker-600 spectrometer (600 MHz), δ in parts per million, J in Hertz, and using TMS as the internal standard. Signal multiplicities are assigned as singlet (s), doublet (d), multiplet (m). All analytical reagents were commercially available and were used directly without further purification.

Synthesis of quinolin-2-yl(quinoxalin-2-yl)methanones ( 3a selected as an example); tipical procedure

A mixture of quinoxaline (1a) (0.13 g, 1.0 mmol), 2-methylquinoline (2a) (0.42 g, 3 mmol), TFA (0.14 g, 1.2 mmol) and TBHP (0.36 g, 4.0 mmol, in decane 5–6 M) in PhCl (8 mL) was stirred at 70 ^oC for 12 hours until the total consumption of (1a)was monitored by TLC. After cooling, the reaction mixture was washed with brine (20 mL) and extracted with CH₂Cl₂ (2 × 20 mL). The combined organic extract was dried over Na₂SO₄ and concentrated under vacuum. The residue was purified by column chromatography (petroleum ether/EtOAc = 10:1) to afford the target product 3a (white solid, 86%, 0.24 g).

Quinolin-2-yl(quinoxalin-2-yl)methanone (3a): White solid; 86%, 0.24 g; mp 193–194 ^oC. ¹H NMR (600 MHz, CDCl₃): δ = 9.60 (s, 1H), 8.36 (d, J = 8.4 Hz, 1H), 8.28–8.26 (m, 2H), 8.24 (d, J = 8.4 Hz, 1H), 8.03 (d, J = 9.2 Hz, 1H), 7.92 (d, J = 7.6 Hz, 1H), 7.84 (t, J = 7.6 Hz, 1H), 7.43 (m, 2H), 7.14 (d, J = 2.6 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃): δ = 191.8, 160.1, 150.6, 150.1, 146.0, 143.2, 142.9, 141.8, 135.6, 132.1, 131.7, 131.1, 130.6, 130.4, 129.3, 123.5, 121.1, 104.8. MS (ESI): m/z (%) = 286.1 ([M+H]⁺, 100). HRMS (ESI): m/z [M+H]⁺ calcd for C₁₈H₁₂N₃O: 286.0980; found: 286.0985.

(3-Methoxyquinolin-2-yl)(quinoxalin-2-yl)methanone (3b): White solid; 59%, 0.18 g; mp 161–162 ^oC. ¹H NMR (600 MHz, CDCl₃): δ = 9.61 (s, 1H), 8.35 (d, J = 8.5 Hz, 1H), 8.28–8.26 (m, 2H), 8.23 (d, J = 8.3 Hz, 1H), 8.07 (d, J = 2.6 Hz, 1H), 8.03 (d, J = 7. 8 Hz, 1H), 7.78 (dd, J = 7.6, 2.6 Hz, 1H), 7.65 (dd, J = 7.6, 1.8 Hz, 1H), 7.45 (dd, J = 7.6, 1.8 Hz, 1H), 3.98 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ = 191.6, 160.7, 150.6, 150.1, 146.0, 143.3, 142.6, 141.9, 135.7, 132.3, 131.7, 131.1, 130.6, 130.5, 129.1, 123.6, 121.1, 104.5, 55.8. MS (ESI): m/z (%) = 316.1 ([M+H]⁺, 100). HRMS (ESI): m/z [M+H]⁺ calcd for C₁₉H₁₄N₃O₂: 316.1064; found: 316.1069.

(3-Bromoquinolin-2-yl)(quinoxalin-2-yl)methanone (3c): White solid; 53%, 0.22 g; mp 153–154 ^oC. 1H NMR (600 MHz, CDCl₃): δ =9.60 (s, 1H), 8.41 (d, J = 8.3 Hz, 1H), 8.30–8.28 (m, 2H), 8.24 (d, J = 8.3 Hz, 1H), 8.08 (d, J = 2.6 Hz, 1H), 8.03 (d, J = 7. 8 Hz, 1H), 7.83 (m, 1H),7.71 (dd, J = 7.6, 1.8 Hz, 1H), 7.52 (dd, J = 7.6, 1.8 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃): δ = 191.7, 155.7, 150.4, 150.1, 146.0, 143.3, 142.6, 141.9, 138.4, 135.8, 132.4, 131.7, 131.3, 130.6, 130.5, 129.1, 123.6, 120.9. MS (ESI): /z (%) = 364.0 ([M+H]⁺, 51), 366.0 ([M+H]⁺, 49). HRMS (ESI): m/z [M+H]⁺ calcd for C₁₈H₁₁⁷⁹BrN₃O: 364.0085; found: 364.0090; C₁₈H₁₁⁸¹BrN₃O: 366.0065; found: 366.0070.

(4-Methoxyquinolin-2-yl)(quinoxalin-2-yl)methanone (3d): White solid; 71%, 0.24 g; mp 101–102 ^oC. ¹H NMR (600 MHz, CDCl₃): δ = 9.61 (s, 1H), 8.29–8.27 (m, 2H), 8.26–8.23 (m, 3H), 8.15 (s, 1H), 8.09 (dd, J = 7. 8, 2.6 Hz, 1H), 7.79 (dd, J = 7.6, 2.8 Hz, 1H), 7.63–7.61 (m, 1H), 3.99 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ = 191.7, 160.7, 150.6, 150.1, 146.0, 143.1, 142.9, 141.9, 135.6, 132.4, 131.7, 131.2, 130.6, 130.5, 129.1, 123.6, 121.1, 104.8, 55.7. MS (ESI): m/z (%) = 316.1 ([M+H]⁺, 100). HRMS (ESI): m/z [M+H]⁺ calcd for C₁₉H₁₄N₃O₂: 316.1064; found: 316.1069.

(4-Chloroquinolin-2-yl)(quinoxalin-2-yl)methanone (3e): White solid; 58%, 0.19 g; mp 113–114 ^oC. ¹H NMR (600 MHz, CDCl₃): δ = 9.60 (s, 1H), 8.33 (d, J = 7.8 Hz, 1H), 8.28–8.24 (m, 4H), 8.07 (dd, J = 7. 6, 2.6 Hz, 1H), 7.80 (dd, J = 7.6, 2.8 Hz, 1H), 7.63–7.60 (m, 2H). ¹³C NMR (100 MHz, CDCl₃): δ = 191.7, 160.8, 158.6, 151.2, 146.5, 143.4, 142.9, 141.4, 135.6, 132.4, 131.5, 131.2, 130.6, 130.3, 129.1, 123.6, 121.1, 114.5. MS (ESI): m/z (%) = 320.1 ([M+H]⁺, 75), 322.1 ([M+H]⁺, 25). HRMS (ESI): m/z [M+H]⁺ calcd for C₁₈H₁₁³⁵ClN₃O: 320.0591; found: 320.0596; C₁₈H₁₁³⁷ClN₃O: 322.0561; found: 322.0566.

(6-Methoxyquinolin-2-yl)(quinoxalin-2-yl)methanone (3f): White solid; 92%, 0.29 g; mp 179–180 ^oC. ¹H NMR (600 MHz, CDCl₃): δ = 9.61 (s, 1H), 8.34 (d, J = 8.5 Hz, 1H), 8.28–8.26 (m, 2H), 8.23 (d, J = 8.3 Hz, 1H), 8.02 (d, J = 9.2 Hz, 1H), 7.91 (t, J = 7.6 Hz, 1H), 7.86 (t, J = 7.6 Hz, 1H), 7.42 (dd, J = 9.2, 2.5 Hz, 1H), 7.16 (d, J = 2.4 Hz, 1H), 3.99 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ = 191.7, 160.0, 150.6, 150.0, 146.0, 143.3, 142.9, 141.9, 135.6, 132.3, 131.7, 131.0, 130.6, 130.5, 129.3, 123.6, 121.1, 104.9, 55.7. MS (ESI): m/z (%) = 316.1 ([M+H]⁺, 100). HRMS (ESI): m/z [M+H]⁺ calcd for C₁₉H₁₄N₃O₂: 316.1064; found: 316.1069.

(6-Chloroquinolin-2-yl)(quinoxalin-2-yl)methanone (3g): White solid; 80%, 0.26 g; mp 185–186 ^oC. ¹H NMR (600 MHz, CDCl₃): δ = 9.60 (s, 1H), 8.36–8.34 (m, 2H), 8.25–8.22 (m, 2H), 8.16–8.14 (m, 1H), 7.92–7.90 (m, 1H), 7.87–7.84 (m, 1H), 7.57–7.53 (m, 2H). ¹³C NMR (100 MHz, CDCl₃): δ = 191.7, 161.1, 152.50, 152.48, 149.4, 145.8, 144.3, 141.7, 136.6, 133.4, 132.0, 130.7, 130.6, 130.3, 129.3, 121.3, 120.8, 110.9. MS (ESI): m/z (%) = 320.1 ([M+H]⁺, 75), 322.1 ([M+H]⁺, 25). HRMS (ESI): m/z [M+H]⁺ calcd for C₁₈H₁₁³⁵ClN₃O: 320.0591; found: 320.0595; C₁₈H₁₁³⁷ClN₃O: 322.0561; found: 322.0567.

(6-Bromoquinolin-2-yl)(quinoxalin-2-yl)methanone (3h): White solid; 83%, 0.30 g; mp 167–168 ^oC. ¹H NMR (600 MHz, CDCl₃): δ = 9.60 (s, 1H), 8.36–8.33 (m, 2H), 8.26–8.23 (m, 2H), 8.16–8.14 (m, 1H), 7.92–7.90 (m, 1H), 7.87–7.84 (m, 1H), 7.57–7.54 (m, 2H). ¹³C NMR (100 MHz, CDCl₃): δ = 191.7, 160.4, 152.3, 152.1, 149.2, 145.6, 144.3, 141.5, 136.6, 133.2, 132.0, 130.4, 130.2, 130.1, 129.1, 121.3, 120.5, 110.2. MS (ESI): m/z (%) = 364.0 ([M+H]⁺, 51), 366.0 ([M+H]⁺, 49). HRMS (ESI): m/z [M+H]⁺ calcd for C₁₈H₁₁⁷⁹BrN₃O: 364.0085; found: 364.0091; C₁₈H₁₁⁸¹BrN₃O: 366.0065; found: 366.0071.

(7-Methoxyquinolin-2-yl)(quinoxalin-2-yl)methanone (3i): White solid; 73%, 0.23 g; mp 166167 ^oC. ¹H NMR (600 MHz, CDCl₃): δ = 9.61 (s, 1H), 8.34 (d, J = 8.6 Hz, 1H), 8.28–8.26 (m, 2H), 8.23 (d, J = 8.4 Hz, –1H), 8.02 (d, J = 9.2 Hz, 1H), 7.92 (s, 1H), 7.86 (d, J = 7.6 Hz, 1H), 7.42 (dd, J = 9.2, 2.5 Hz, 1H), 7.17 (d, J = 2.4 Hz, 1H), 3.98 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ = 191.7, 160.1, 150.6, 150.0, 146.0, 143.3, 142.9, 141.9, 135.4, 132.3, 131.7, 131.1, 130.6, 130.5, 129.3, 123.4, 121.1, 104.8, 55.8. MS (ESI): m/z (%) = 316.1 ([M+H]⁺, 100). HRMS (ESI): m/z [M+H]⁺ calcd for C₁₉H₁₄N₃O₂: 316.1064; found: 316.1069.

(7-Chloroquinolin-2-yl)(quinoxalin-2-yl)methanone (3j): White solid; 62%, 0.25 g; mp 175–176 ^oC. ¹H NMR (600 MHz, CDCl₃): δ = 9.60 (s, 1H), 8.40 (s, 1H), 8.33 (d, J = 7.8 Hz, 1H), 8.28–8.26 (m, 2H), 8.23 (d, J = 8.4 Hz, 1H), 8.07 (dd, J = 7. 6, 2.6 Hz, 1H), 7.94 (dd, J = 7.6, 2.8 Hz, 1H), 7.63–7.61 (m, 2H). ¹³C NMR (100 MHz, CDCl₃): δ = 191.7, 160.8, 158.5, 151.2, 146.4, 143.4, 142.8, 141.4, 135.6, 132.4, 131.6, 131.2, 130.7, 130.3, 129.1, 123.5, 121.0, 111.5. MS (ESI): m/z (%) = 320.1 ([M+H]⁺, 75), 322.1 ([M+H]⁺, 25). HRMS (ESI): m/z [M+H]⁺ calcd for C₁₈H₁₁³⁵ClN₃O: 320.0591; found: 320.0596; C₁₈H₁₁³⁷ClN₃O: 322.0561; found: 322.0567.

(8-Methoxyquinolin-2-yl)(quinoxalin-2-yl)methanone (3k): White solid; 79%, 0.24 g; mp 105-106 ^oC. ¹H NMR (600 MHz, CDCl₃): δ = 9.61 (s, 1H), 8.34 (d, J = 8.5 Hz, 1H), 8.27–8.25 (m, 2H), 8.23 (d, J = 8.3 Hz, 1H), 8.06 (d, J = 7.6 Hz, 1H), 7.81 (dd, J = 7.8, 2.6 Hz, 1H), 7.70 (dd, J = 7.8, 2.6 Hz, 1H), 7.44 (dd, J = 7.6, 1.8 Hz, 1H), 7.26 (d, J = 7.6 Hz, 1H), 3.98 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ = 191.7, 160.1, 150.6, 150.1, 146.0, 143.3, 142.9, 141.7, 135.5, 132.3, 131.7, 131.1, 130.6, 130.5, 129.3, 123.6, 121.2, 107.9, 55.8. MS (ESI): m/z (%) = 316.1 ([M+H]⁺, 100). HRMS (ESI): m/z [M+H]⁺ calcd for C₁₉H₁₄N₃O₂: 316.1064; found: 316.1069.

(8-Bromoquinolin-2-yl)(quinoxalin-2-yl)methanone (3l): White solid; 51%, 0.19 g; mp 96–97 ^oC. ¹H NMR (600 MHz, CDCl₃): δ = 9.60 (s, 1H), 8.34 (d, J = 8.5 Hz, 1H), 8.28–8.26 (m, 2H), 8.23 (d, J = 8.3 Hz,1H), 8.03 (d, J = 7.6 Hz, 1H), 7.95 (dd, J = 7.8, 2.6 Hz, 1H), 7.76 (d, J = 7.6, 1H), 7.67–7.64 (m, 2H). ¹³C NMR (100 MHz, CDCl₃): δ = 191.7, 160.8, 158.7, 151.2, 146.4, 143.4, 142.9, 141.4, 135.7, 132.4, 131.6, 131.1, 130.7, 130.5, 129.1, 123.5, 121.2, 112.0. MS (ESI): m/z (%) = 364.0 ([M+H]⁺, 51), 366.0 ([M+H]⁺, 49). HRMS (ESI): m/z [M+H]⁺ calcd for C₁₈H₁₁⁷⁹BrN₃O: 364.0085; found: 364.0091; C₁₈H₁₁⁸¹BrN₃O: 366.0065; found: 366.0070.

(3-Methylquinoxalin-2-yl)(quinolin-2-yl)methanone (3m): White solid; 45%, 0.14 g; mp 135–136 ^oC. ¹H NMR (600 MHz, CDCl₃): δ = 8.37 (d, J = 8.5 Hz, 1H), 8.31–8.29 (m, 1H), 8.12 (dd, J = 8.2, 2.6 Hz, 1H), 8.09 (d, J = 8.2 Hz, 1H), 8.08–8.06 (m, 1H), 8.02 (d, J = 8.4 Hz, 1H), 7.96 (d, J = 8.4 Hz, 1H), 7.82–7.79 (m, 2H), 7.68–7.66 (m, 1H), 2.67 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ = 192.1, 153.2, 149.3, 147.2, 145.7, 143.2, 141.8, 141.0, 137.1, 134.0, 130.7, 130.2, 129.3, 129.1, 128.8, 127.6, 122.3, 120.6, 21.9. MS (ESI): m/z (%) = 300.1 ([M+H]⁺, 100). HRMS (ESI): m/z [M+H]⁺ calcd for C₁₉H₁₄N₃O₂: 300.1117; found: 300.1122.

(3-Chloroquinoxalin-2-yl)(quinolin-2-yl)methanone (3n): White solid; 49%, 0.16 g; mp 130–131 ^oC. ¹H NMR (600 MHz, CDCl₃): δ = 8.44 (d, J = 8.4 Hz, 1H), 8.36–8.34 (m, 1H), 8.17 (dd, J = 8.3, 2.6 Hz, 1H), 8.11 (d, J = 8.2 Hz, 1H), 8.08–8.06 (m, 1H), 8.02 (d, J = 8.4 Hz, 1H), 7.95 (d, J = 8.4 Hz, 1H), 7.82–7.78 (m, 2H), 7.68–7.66 (m, 1H). ¹³C NMR (100 MHz, CDCl₃): δ = 192.1, 154.0, 149.2, 147.3, 145.7, 143.6, 141.7, 141.0, 137.2, 134.0, 131.7, 130.2, 129.3, 129.5, 128.8, 127.6, 122.7, 121.3. MS (ESI): m/z (%) = 320.1 ([M+H]⁺, 75), 322.1 ([M+H]⁺, 25). HRMS (ESI): m/z [M+H]⁺ calcd for C₁₈H₁₁³⁵ClN₃O: 320.0591; found: 320.0597; C₁₈H₁₁³⁷ClN₃O: 322.0561; found: 322.0568.

(6-Methylquinoxalin-2-yl)(quinolin-2-yl)methanone (3o) + (7-methylquinoxalin-2-yl)(quinolin-2-yl)methanone (3o′) (1:1): White solid; 55%, 0.17 g. ¹H NMR (600 MHz, CDCl₃): δ = 9.64 (s, 1H), 9.58 (s, 1H), 8.43 (d, J = 8.5 Hz, 2H), 8.33 (d, J = 8.5 Hz, 2H), 8.19–8.16 (m, 2H), 8.13 (d, J = 17.0 Hz, 2H), 8.02 (d, J = 16.5 Hz, 2H), 7.96 (d, J = 8.0 Hz, 2H), 7.82–7.79 (m, 2H), 7.76–7.75 (m, 1H), 7.73–7.69 (m, 3H), 2.68 (s, 3H), 2.65 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ = 192.2, 192.0, 153.23, 153.19, 149.3, 148.5, 147.22, 147.21, 146.1, 145.1, 143.2, 143.1, 141.9, 141.6, 141.3, 140.3, 137.19, 137.17, 134.4, 133.1, 130.73, 130.71, 130.3, 130.2, 129.4, 129.34, 129.30, 129.05, 129.04, 128.8, 128.1, 127.7, 127.4, 123.8, 120.69, 120.65, 22.2, 21.9. MS (ESI): m/z (%) = 300.1 ([M+H]⁺, 100). HRMS (ESI): m/z [M+H]⁺ calcd for C₁₉H₁₄N₃O₂: 300.1117; found: 300.1122.

(6-Chloroquinoxalin-2-yl)(quinolin-2-yl)methanone (3p) + (7-chloroquinoxalin-2-yl)(quinolin-2-yl)methanone (3p′) (1:1): White solid; 61%, 0.20 g. ¹H NMR (600 MHz, CDCl₃): δ = 9.63 (s, 1H), 9.58 (s, 1H), 8.44 (d, J = 8.5 Hz, 2H), 8.33 (d, J = 8.5 Hz, 2H), 8.18–8.16 (m, 2H), 8.14–8.11 (m, 2H), 8.02 (d, J = 16.5 Hz, 2H), 7.97 (d, J = 8.0 Hz, 2H), 7.82–7.78 (m, 2H), 7.77–7.76 (m, 1H), 7.75–7.70 (m, 3H). ¹³C NMR (100 MHz, CDCl₃): δ = 192.1, 192.0, 153.5, 153.3, 149.3, 148.5, 147.4, 147.3, 146.1, 145.4, 143.3, 143.1, 141.9, 141.5, 141.3, 140.3, 137.3, 137.2, 134.5, 133.1, 130.8, 130.7, 130.3, 130.2, 129.4, 129.4, 129.3, 129.1, 129.0, 128.8, 128.2, 127.7, 127.5, 123.8, 120.7, 120.6. MS (ESI): m/z (%) = 320.1 ([M+H]⁺, 75), 322.1 ([M+H]⁺, 25). HRMS (ESI): m/z [M+H]⁺ calcd for C₁₈H₁₁³⁵ClN₃O: 320.0591; found: 320.0597; C₁₈H₁₁³⁷ClN₃O: 322.0561; found: 322.0568.

Pyridin-2-yl(quinoxalin-2-yl)methanone (5): White solid; 41%, 0.10 g; mp 178–179 ^oC. ¹H NMR (600 MHz, CDCl₃): δ = 9.64 (s, 1H), 8.90 (d, J = 8.4 Hz, 1H), 8.36 (d, J = 8.6 Hz, 1H), 8.28–8.25 (m, 2H), 8.23 (d, J = 8.6 Hz, 1H), 8.20 (dd, J = 7.8, 2.2 Hz, 1H), 8.10–8.08 (m, 1H), 7.71–7.69 (m, 1H). ¹³C NMR (100 MHz, CDCl₃): δ = 191.2, 160.3, 150.7, 150.3, 146.1, 142.7, 135.4, 131.6, 130.5, 130.1, 128.8, 128.5, 123.5, 122.7. MS (ESI): m/z (%) = 236.1 ([M+H]⁺, 100). HRMS (ESI): m/z [M+H]⁺ calcd for C₁₄H₁₀N₃O: 236.0824; found: 236.0829.

Diquinolin-2-ylmethanone (7): White solid; 39%, 0.11 g; mp 198-199 ^oC. ¹H NMR (600 MHz, CDCl₃): δ = 8.06 (d, J = 8.6 Hz, 2H), 8.02 (d, J = 8.4 Hz, 2H), 7.97 (dd, J = 8.4, 2.6 Hz, 2H), 7.83–7.79 (m, 4H), 7.69–7.66 (m, 2H). ¹³C NMR (100 MHz, CDCl₃): δ = 191.7, 153.1, 147.2, 143.2, 141.0, 134.1, 131.1, 129.4, 127.6, 121.1. MS (ESI): m/z (%) = 285.1 ([M+H]⁺, 100). HRMS (ESI): m/z [M+H]⁺ calcd for C₁₉H₁₃N₂O: 285.1028; found: 285.1033.

Quinoline-2-carbaldehyde (8a): Pale yellow solid; 95%, 0.15 g; mp 66–67 ^oC. ¹H NMR (600 MHz, CDCl₃): δ = 10.24 (s, 1H), 8.31 (d, J = 8.4 Hz, 1H), 8.26 (d, J = 8.4 Hz, 1H), 8.04 (d, J = 8.4 Hz, 1H), 7.91 (d, J = 8.2 Hz, 1H), 7.83 (t, J = 8.2 Hz, 1H), 7.70 (t, J = 7.5 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃): δ = 193.7, 152.6, 147.9, 137.4, 130.5, 130.4, 130.1, 129.2, 127.9, 117.3.

Supplemental Material

sj-doc-1-chl-10.1177_17475198221126026 – Supplemental material for Homolytic aromatic substitution of acyl radicals: Oxidative coupling of 2-methylquinolines with quinoxalines

Supplemental material, sj-doc-1-chl-10.1177_17475198221126026 for Homolytic aromatic substitution of acyl radicals: Oxidative coupling of 2-methylquinolines with quinoxalines by Xue Li, Xian Hao Wu, Jia Feng Yu, Yuan Yuan Zhang, Zhong Ke Hou and Yuan Yuan Xie in Journal of Chemical Research

Footnotes

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: We are grateful to the Natural Science Foundation of Jiangxi Province (20212BAB206073) for financial support.

ORCID iD

YuanYuan Xie

Supplemental material

Supplemental material for this article is available online.

References

Duncton

MAJ

. Med Chem Commun 2011; 12: 1135–1161.

Matcha

Antonchick

AP.

Angew Chem Int Ed 2013; 52: 2082–2086.

Shi

ZJ.

Chem Soc Rev 2012; 41: 5588–5598.

Hanan

Ashraf

Omneya

MK.

Arch Pharmacal Res 2004; 27: 1093–1098.

TenBrink

Sethy

, et al. J Med Chem 1994; 37: 758–768.

Ling

, et al. J Pharm Pharmacol 2007; 59: 695–701.

Kamei

Pulm Pharmacol 1996; 9: 349–356.

Chen

Zhu

Liu

, et al. J Med Chem 2001; 44: 4001–4010.

Wertz

Leifert

Studer

Org Lett 2013; 15: 928–931.

10.

Tang

Song

, et al. J Am Chem Soc 2010; 132: 8900–8902.

11.

Chan

Zhou

Chan

ASC

, et al. Org Lett 2010; 12: 3926–3929.

12.

Wang

Rao

Hua

, et al. Org Lett 2012; 14: 902–905.

13.

Rao

Liu

, et al. Adv Synth Catal 2013; 355: 2191–2196.

14.

Minisci

Vismara

Fontana

Heterocycles 1989; 28: 489–519.

15.

Harrowven

Sutton

BJ.

Prog Heterocycl Chem 2004; 16: 27–53.

16.

Yuan

Liu

, et al. Org Biomol Chem 2018; 16: 3203–3212.

17.

Siddaraju

Lamani

Prabhu

KR.

J Org Chem 2014; 79: 3856–3865.

18.

Zhang

, et al. Chem Commun 2018; 54: 5744–5747.

19.

Rahim

Shaik

Alarifi

, et al. Org Biomol Chem 2018; 16: 635–644.

20.

Chen

Wan

Hua

, et al. Org Biomol Chem 2015; 13: 11561–11566.

21.

Ali

Behera

Guin

, et al. J Org Chem 2015; 80: 5625–5632.

22.

Sakamoto

Sakasai

Yamanaka

Chem Pharm Bull 1980; 28: 571.

23.

Minisci

Vismara

Fonatana

J Org Chem 1989; 54: 5224.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.41 MB